---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002940"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:49:30.339114+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iBio raises $26M in PIPE led by Frazier Life Sciences to fund cardiometabolic programs

## Summary
- Gross proceeds of ~$26M from sale of 11.06M shares/pre-funded warrants at $2.35/share.
- Expected close on Jan 13, 2026; led by Frazier Life Sciences with other existing investors.
- Proceeds to advance IBIO-610, IBIO-600, and myostatin/activin A bispecific programs.
- Company expects cash runway extended into calendar 2028.
- Leerink Partners lead placement agent; LifeSci Capital and Oppenheimer co-agents.

## SEC filing metadata
- accession: 0001104659-26-002940
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/tm262944d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002940
- JSON: https://secwatch.observer/filing/0001104659-26-002940.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002940.txt

## Key facts
- Material Agreements
  iBio, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $26 million (effective 2026-01-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $26 million
  - Effective: 2026-01-08
  source text: On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.